Astrazeneca plc ADR (AZN) concluded trading on Wednesday at a closing price of $73.0, with 5.02 million shares of worth about $366.32 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 7.42% during that period and on July 23, 2025 the price saw a gain of about 3.58%. Currently the company’s common shares owned by public are about 3.10B shares, out of which, 3.10B shares are available for trading.
Stock saw a price change of 4.17% in past 5 days and over the past one month there was a price change of 3.34%. Year-to-date (YTD), AZN shares are showing a performance of -7.25% which increased to 11.42% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $61.24 but also hit the highest price of $87.68 during that period. The average intraday trading volume for Astrazeneca plc ADR shares is 4.46 million. The stock is currently trading 3.74% above its 20-day simple moving average (SMA20), while that difference is up 3.11% for SMA50 and it goes to 3.29% higher than SMA200.
Astrazeneca plc ADR (NASDAQ: AZN) currently have 3.10B outstanding shares and institutions hold larger chunk of about 16.63% of that.
The stock has a current market capitalization of $226.40B and its 3Y-monthly beta is at 0.36. PE ratio of stock for trailing 12 months is 29.33, while it has posted earnings per share of $2.49 in the same period. Its PEG reads 2.55 and has Quick Ratio of 0.70 while making debt-to-equity ratio of 0.77. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AZN, volatility over the week remained 1.50% while standing at 1.48% over the month.
Stock’s fiscal year EPS is expected to rise by 10.03% while it is estimated to increase by 13.27% in next year. EPS is likely to shrink at an annualized rate of 11.48% for next 5-years, compared to annual growth of 34.63% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Exane BNP Paribas on April 15, 2025 offering an Outperform rating for the stock and assigned a target price of $75 to it. Stock get a Hold rating from Deutsche Bank on November 06, 2024.
